-
1 Comment
Shenzhen Hepalink Pharmaceutical Group Co., Ltd is currently in a long term downtrend where the price is trading 16.2% below its 200 day moving average.
From a valuation standpoint, the stock is 54.3% cheaper than other stocks from the Healthcare sector with a price to sales ratio of 4.4.
Shenzhen Hepalink Pharmaceutical Group Co., Ltd's total revenue rose by 20.5% to $2B since the same quarter in the previous year.
Its net income has dropped by 18.7% to $316M since the same quarter in the previous year.
Finally, its free cash flow grew by 72.2% to $-45M since the same quarter in the previous year.
Based on the above factors, Shenzhen Hepalink Pharmaceutical Group Co., Ltd gets an overall score of 3/5.
| ISIN | CNE100000P02 |
|---|---|
| Sector | Healthcare |
| Industry | Drug Manufacturers - Specialty & Generic |
| Exchange | SHE |
| CurrencyCode | CNY |
| Beta | 0.37 |
|---|---|
| Target Price | 8.3 |
| Dividend Yield | 1.7% |
| Market Cap | 19B |
| PE Ratio | 31.36 |
Shenzhen Hepalink Pharmaceutical Group Co., Ltd. provides pharmaceutical products in Hong Kong, the United States, Europe, Mainland China, and internationally. It operates in four segments: Finished Dose Pharmaceutical Products, Active Pharmaceutical Ingredients (API), Contract Development and Manufacturing Organization (CDMO), and Others. The company offers finished dose pharmaceutical products, such as prolongin, inhixa, neoparin, and heparin and enoxaparin sodium injections; API products, including heparin and enoxaparin sodium APIs; and pancreatin API. It also provides molecule biologics CDMO services, which include research and development, manufacturing, quality management, and program management services, as well as technical support services. In addition, the company develops apabetalone (RVX-208), a BET bromodomain protein inhibitor in Phase 3 trial to reduce major adverse cardiovascular events, as well as in Phase 2 trial for diabetic nephropathy and fatty disease; oregovomab, a monoclonal antibody in Phase 3 trial for ovarian cancer, as well as in Phase 2 for pancreatic cancer; tosatoxumab (AR-301), a fully human IgG1 monoclonal antibody in Phase 3 trial for ventilator-associated pneumonia; AR20.5 in Phase 2 trial for pancreatic cancer; AR-101 in Phase 2 trial for ventilator-associated pneumonia; and H1710, a heparanase inhibitor preparation for solid tumors. Further, it engages in property management, investment management and consulting, biopharmaceutical technology development and consulting, and equity and venture investment activities; provision of services on pharmaceutical related activities; and trading of medical and biopharmaceutical products. The company was formerly known as Shenzhen Hepalink Pharmaceutical Co.,Ltd. and changed its name to Shenzhen Hepalink Pharmaceutical Group Co., Ltd. in February 2017. Shenzhen Hepalink Pharmaceutical Group Co., Ltd. was founded in 1998 and is headquartered in Shenzhen, the People's Republic of China.
Learn MoreHere's how to backtest a trading strategy or backtest a portfolio for 002399.SHE using our backtest tool. PyInvesting provides the backtesting software for you to backtest your investment strategy. Our backtest software is written using Python code and allows you to backtest stock, backtest etf, backtest options, backtest crypto and backtest forex online. Our backtesting Python framework is highly robust and gives you a realistic simulation of how your strategy would have performed in the past using backtest data.
© PyInvesting 2025
